Arcutis Biotherapeutics, Inc.
ARQT
$20.43
-$0.29-1.40%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 81.50M | 63.85M | 69.36M | 44.76M | 30.86M |
| Total Other Revenue | -- | 2.00M | 2.00M | -- | -- |
| Total Revenue | 81.50M | 65.85M | 71.36M | 44.76M | 30.86M |
| Cost of Revenue | 7.49M | 8.83M | 6.91M | 5.50M | 3.46M |
| Gross Profit | 74.01M | 57.02M | 64.46M | 39.25M | 27.39M |
| SG&A Expenses | 69.17M | 64.00M | 57.61M | 58.82M | 58.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.12M | 90.38M | 78.99M | 83.82M | 80.94M |
| Operating Income | -14.61M | -24.53M | -7.63M | -39.07M | -50.08M |
| Income Before Tax | -15.54M | -24.78M | -10.47M | -41.54M | -52.33M |
| Income Tax Expenses | 342.00K | 279.00K | 323.00K | -- | -- |
| Earnings from Continuing Operations | -15.89M | -25.06M | -10.79M | -41.54M | -52.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.89M | -25.06M | -10.79M | -41.54M | -52.33M |
| EBIT | -14.61M | -24.53M | -7.63M | -39.07M | -50.08M |
| EBITDA | -14.20M | -21.40M | -7.17M | -37.63M | -50.06M |
| EPS Basic | -0.13 | -0.20 | -0.09 | -0.33 | -0.42 |
| Normalized Basic EPS | -0.08 | -0.12 | -0.05 | -0.21 | -0.26 |
| EPS Diluted | -0.13 | -0.20 | -0.09 | -0.33 | -0.42 |
| Normalized Diluted EPS | -0.08 | -0.12 | -0.05 | -0.21 | -0.26 |
| Average Basic Shares Outstanding | 127.00M | 126.04M | 124.92M | 124.30M | 123.48M |
| Average Diluted Shares Outstanding | 127.00M | 126.04M | 124.92M | 124.30M | 123.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |